04.07.2014 • NewsDede Willamsjoint ventureJV

Mitsubishi and Sabic Name Start-Up Date for Saudi MMA

Japan's Mitsubishi Rayon (MRC) and Saudi petrochemical giant Sabic have announced a start-up date of mid-2017 for their MMA and PMMA plants at Al Jubail / Saudi Arabia.

Initial plans for the investment were announced in mid-2011. The plants will be operated by the 50:50 joint venture Saudi Methacrylates.

The MMA plant, with 250,000 t/y of capacity using the "Alpha" technology of MRC subsidiary Lucite will be the world's largest, the companies said. The PMMA facility, which will use an MRC process will have an output capability of 40,000 t/y.

Asia-wide engineering group CTCI Corporation of Taiwan has been tapped to build both plants.

Gas feedstock for the complex will sourced locally in Saudi Arabia. With MMA monomer demand forecast to continue growing at 1.5-2% above global GDP, Mitsubishi said Saudi Methacrylates will be a "strategic supply base for growing emerging markets such as those of Eastern Europe, India, the Middle East and Africa.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.